High-grade glioma
Conditions
Interventions
Collaborative treatmnt of concomitant radio-chemotherapy with activated DC vaccine to high-grade glioma patients
Sponsors
Shizuoka Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histological diagnosis of high-grade glioma (WHO Gr3-4) 2. Concomitant chemo-radiation treatment is going to be given after surgery 3. 20 <=Age< 80 4. Performance status; 0-2 5. Measurable lesions in imaging diagnosis 6. HLA genotyping; HLA-A2 or A24 7. No severe organ dysfunction 8. No severe hematostatic dysfunction 9. Informed consents obtained from patients or family members 10. Survival for more than 6 months expected 11. More than 4 weeks interval after last treatment against cancer
Exclusion criteria
Exclusion criteria: 1. Within 28 days afetr the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall survival time Antitumor effect Immunological effect | — |
Primary
| Measure | Time frame |
|---|---|
| Relapse-free survival time | — |
Countries
Japan
Contacts
Public ContactYasuto Akiyama, M.D.
Shizuoka Cancer Center Research Institute Immunotherapy Division
Outcome results
None listed